# ALKS catalysts: Alkermes plc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/alks/catalysts

> Alkermes plc. (ALKS) has 14 upcoming catalysts. The next is the alks 2680 dose 1 primary completion, May 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Alkermes plc. |
| Ticker | ALKS (Nasdaq) |
| SEC CIK | 1520262 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/alks |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 29, 2018 | [Aristada Initio Kit (aripiprazole lauroxil) FDA approval](https://sec-api.dev/pdufa/aripiprazole-lauroxil) | ALKS |  | completed, approved | "NDA209830 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20180629, review_priority STANDARD; sponsor_name ALKERMES INC; product ARISTADA INITIO KIT (ARIPIPRAZOLE LAUROXIL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209830%22)) |
| November 13, 2020 | [Lybalvi (olanzapine; samidorphan l-malate) complete response letter (CRL)](https://sec-api.dev/pdufa/olanzapine-samidorphan-l-malate) | ALKS |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22213378Orig1Orig2s000OtherActionLtrs.pdf%22)) |
| May 28, 2021 | [Lybalvi (olanzapine; samidorphan l-malate) FDA approval](https://sec-api.dev/pdufa/olanzapine-samidorphan-l-malate) | ALKS |  | completed, approved | "NDA213378 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20210528, review_priority STANDARD; sponsor_name ALKERMES INC; product LYBALVI (OLANZAPINE; SAMIDORPHAN L-MALATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213378%22)) |
| May 1, 2023 | [Lumryz (sodium oxybate) FDA approval](https://sec-api.dev/pdufa/oxybate) | ALKS |  | completed, approved | "NDA214755 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20230501, review_priority STANDARD; sponsor_name ALKERMES INC; product LUMRYZ (SODIUM OXYBATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214755%22)) |
| October 16, 2024 | [Lumryz (sodium oxybate) label expansion decision](https://sec-api.dev/pdufa/oxybate) | ALKS |  | completed, approved | "NDA214755 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20241016, review_priority STANDARD; sponsor_name ALKERMES INC; product LUMRYZ (SODIUM OXYBATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214755%22)) |
| February 12, 2025 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000095017025018402/alks-ex99_1.htm)) |
| May 1, 2025 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000095017025061441/alks-ex99_1.htm)) |
| June 19, 2025 | [Alks 2680 dose 1 primary completion](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 1 | completed | "NCT06358950 (A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06358950)) |
| July 21, 2025 | [Neuropeptide topline data readout](https://sec-api.dev/pdufa/neuropeptide) | ALKS | narcolepsy type 1 | completed, positive | "DUBLIN, July 21, 2025 -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000095017025097323/alks-ex99_1.htm)) |
| July 29, 2025 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000095017025099382/alks-ex99_1.htm)) |
| October 28, 2025 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000119312525252207/alks-ex99_1.htm)) |
| November 11, 2025 | [Alks 2680 dose 1 primary completion](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 2 | completed | "NCT06555783 (A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-11 (ACTUAL); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06555783)) |
| November 12, 2025 | [Neuropeptide topline data readout](https://sec-api.dev/pdufa/neuropeptide) | ALKS | narcolepsy type 2 | completed, positive | "DUBLIN, Nov. 12, 2025 -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton in patients with narcolepsy type 2 (NT2)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000119312525276161/alks-ex99_1.htm)) |
| February 25, 2026 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000119312526068512/alks-ex99_1.htm)) |
| May 5, 2026 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000119312526205008/alks-ex99_1.htm)) |
| May 12, 2026 | [LUMRYZ (lumryz) topline data readout](https://sec-api.dev/pdufa/lumryz) | ALKS | idiopathic hypersomnia | completed, positive | "On May 12, 2026, the Company announced positive topline results from REVITALYZSM, a double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ® (sodium oxybate) extended-release oral suspension compared to placebo in adults with idiopathic hypersomnia." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1520262/000119312526218150/alks-20260512.htm)) |
| July 28, 2026 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000119312526318844/alks-ex99_1.htm)) |
| late 2026 | [Alkermes plc. topline data readout](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | scheduled | "With our first ADHD data for ALKS 7290 expected in the coming months and topline results from our alixorexton phase 2 idiopathic hypersomnia study expected toward year-end, we are generating significant new datasets that may open new opportunities for our orexin 2 receptor portfolio," said Blair Jackson, Chief Operating Officer of Alkermes." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000119312526318844/alks-ex99_1.htm)) |
| September 2026 | [Olz/sam primary completion](https://sec-api.dev/pdufa/olz-sam) | ALKS | Schizophrenia; Bipolar I Disorder | delayed | "NCT05303064 (Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05303064)) |
| Sep to Dec 2026 | [Olz/sam topline data readout](https://sec-api.dev/pdufa/olz-sam) | ALKS | Schizophrenia; Bipolar I Disorder | scheduled | "NCT05303064 (Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05303064)) |
| September 21, 2026 | [Neuropeptide topline data readout](https://sec-api.dev/pdufa/neuropeptide) | ALKS | attention-deficit hyperactivity disorder | completed, positive | "On September 21, 2026, the Company announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the Company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/alks-20260921.htm)) |
| November 2026 | [Alks 2680 dose 1 primary completion](https://sec-api.dev/pdufa/alks-2680) | ALKS | Idiopathic Hypersomnia | scheduled | "NCT06843590 (A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06843590)) |
| Nov 2026 to Feb 2027 | [Alks 2680 dose 1 topline data readout](https://sec-api.dev/pdufa/alks-2680) | ALKS | Idiopathic Hypersomnia | scheduled | "NCT06843590 (A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06843590)) |
| November 3, 2026 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000119312526444381/alks-ex99_1.htm)) |
| May 2027 | [Alks 2680 dose 1 primary completion](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 1 | scheduled | "NCT07455383 (A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07455383)) |
| May to Aug 2027 | [Alks 2680 dose 1 topline data readout](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 1 | scheduled | "NCT07455383 (A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07455383)) |
| May 2027 | [Alks 2680 dose 1 primary completion](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 2 | scheduled | "NCT07502443 (A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07502443)) |
| May to Aug 2027 | [Alks 2680 dose 1 topline data readout](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 2 | scheduled | "NCT07502443 (A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07502443)) |
| June 2027 | [Alks 2680 dose 1 primary completion](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 1 | scheduled | "NCT07540897 (A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07540897)) |
| Jun to Sep 2027 | [Alks 2680 dose 1 topline data readout](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 1 | scheduled | "NCT07540897 (A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07540897)) |
| July 2027 | [ALKS-7290 primary completion](https://sec-api.dev/pdufa/alks-7290) | ALKS | Attention Deficit Disorder With Hyperactivity (ADHD) | scheduled | "NCT07755410 (A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07755410)) |
| Jul to Oct 2027 | [ALKS-7290 topline data readout](https://sec-api.dev/pdufa/alks-7290) | ALKS | Attention Deficit Disorder With Hyperactivity (ADHD) | scheduled | "NCT07755410 (A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07755410)) |
| September 2027 | [Olz/sam primary completion](https://sec-api.dev/pdufa/olz-sam) | ALKS | Bipolar I Disorder; Schizophrenia | scheduled | "NCT04987229 (Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04987229)) |
| Sep to Dec 2027 | [Olz/sam topline data readout](https://sec-api.dev/pdufa/olz-sam) | ALKS | Bipolar I Disorder; Schizophrenia | scheduled | "NCT04987229 (Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04987229)) |
| January 2028 | [Alks 7290 dose primary completion](https://sec-api.dev/pdufa/alks-7290-dose) | ALKS | Major Depressive Disorder (MDD) | scheduled | "NCT07901179 (A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07901179)) |
| Jan to Apr 2028 | [Alks 7290 dose topline data readout](https://sec-api.dev/pdufa/alks-7290-dose) | ALKS | Major Depressive Disorder (MDD) | scheduled | "NCT07901179 (A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07901179)) |
| June 2030 | [Alks 2680 dose 1 primary completion](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia | scheduled | "NCT06767683 (A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-06 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06767683)) |
| Jun to Sep 2030 | [Alks 2680 dose 1 topline data readout](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia | scheduled | "NCT06767683 (A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-06 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06767683)) |

## Drugs

- [Alks 2680 dose 1](https://sec-api.dev/pdufa/alks-2680): Narcolepsy Type 2, Narcolepsy Type 1, Idiopathic Hypersomnia
- [ALKS-7290](https://sec-api.dev/pdufa/alks-7290): Attention Deficit Disorder With Hyperactivity (ADHD)
- [Alks 7290 dose](https://sec-api.dev/pdufa/alks-7290-dose): Major Depressive Disorder (MDD)
- [Aristada Initio Kit (aripiprazole lauroxil)](https://sec-api.dev/pdufa/aripiprazole-lauroxil): 
- [LUMRYZ (lumryz)](https://sec-api.dev/pdufa/lumryz): idiopathic hypersomnia
- [Neuropeptide](https://sec-api.dev/pdufa/neuropeptide): attention-deficit hyperactivity disorder, narcolepsy type 2, narcolepsy type 1
- [Lybalvi (olanzapine; samidorphan l-malate)](https://sec-api.dev/pdufa/olanzapine-samidorphan-l-malate): 
- [Olz/sam](https://sec-api.dev/pdufa/olz-sam): Bipolar I Disorder, Schizophrenia
- [Lumryz (sodium oxybate)](https://sec-api.dev/pdufa/oxybate): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/alks/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ALKS catalysts: Alkermes plc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/alks/catalysts

```bibtex
@misc{secapidev_companies_alks_catalysts_20261116,
  title        = {ALKS catalysts: Alkermes plc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/alks/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_alks_catalysts_20261116","title":"ALKS catalysts: Alkermes plc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/alks/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
